ALLIANCE A051701 randomised 73 patients with newly diagnosed double-hit lymphoma to dose-adjusted EPOCH-R with or without venetoclax. Median age was 65, 89% had MYC-BCL2 double-hit disease, 86% had advanced stage, and 64% were high or high-intermediate IPI risk. Median follow-up was 34.7 months.
On efficacy, nothing was gained: median progression-free survival was 7.7 months with venetoclax and 28.4 months without, a hazard ratio of 1.13 with an interval from 0.53 to 2.37. With that interval the trial cannot distinguish benefit from harm on progression, and should not be read as showing either.
On safety it is unambiguous. Six of 37 patients (17%) in the venetoclax arm died on treatment — four from sepsis, three of those at least possibly treatment-related, and two from cardiac arrest — against one of 36 (3%) in the control arm. The double-hit cohort was closed early. Twenty-four-month overall survival was 52% with venetoclax and 72% without, a hazard ratio of 2.49 with an interval from 1.03 to 6.04.
The rationale for adding a BCL2 inhibitor to a MYC-BCL2 driven lymphoma was sound. It did not survive contact with a myelosuppressive backbone in patients with a median age of 65.
- Do not add venetoclax to DA-EPOCH-R in double-hit lymphoma outside a trial
- Four of the six treatment deaths were sepsis, on an already myelosuppressive regimen
- Febrile neutropenia was 43% against 37% — the mortality gap is larger than that gap explains
- 73 patients, so the progression-free survival comparison is uninformative either way
- Overall survival hazard ratio 2.49 with an interval only just excluding 1.0
The statistics, in plain English
The overall survival hazard ratio of 2.49 with an interval from 1.03 to 6.04 only just excludes 1.0, and with 73 patients the estimate is imprecise — the true harm could be near-doubling or six-fold. That imprecision is not a reason to discount it. When a trial stops early for deaths, the ethical threshold is met long before the statistical one, and demanding a tighter interval would mean continuing to randomise patients to find out.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free